G Kees Hovingh
Chief Scientific Advisor, Novo Nordisk A/S
Kees Hovingh is Chief Scientific Advisor at Novo Nordisk and to provide scientific advice and clinical guidance on the R&D strategy to address clinical needs for individuals living with obesity, diabetes and/or cardiovascular disease.
Kees received his PhD in 2005 and his MBA degree in 2016 and is a full professor, internist and vascular medicine specialist. He saw patients until end 2024 at the Amsterdam University Medical Center. His research focuses on genetics and molecular biology in CVD, and he did a post-doctoral fellowship at Harvard Genetics. Kees co-authored over 390 publications (Scholar H index: 114).